Literature DB >> 7452451

Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine.

R A Upton, J N Buskin, R L Williams, N H Holford, S Riegelman.   

Abstract

On the average, 0.6% of a dose of ketoprofen or naproxen or 1.2% of a dose of probenecid was found in the urine of normal male volunteers assayed immediately after its collection. Between approximately 60 and 85% of the dose of these drugs can be excreted in the urine as conjugates, which rapidly hydrolyze at body temperature, at room temperature, and even during frozen storage, thereby regenerating the parent drug. Since urine collections involved sample retention in the bladder at 37 degrees for collection intervals as long as 2--3 hr, the given percentages excreted unchanged probably are overestimates. It is possible that no unchanged ketoprofen, naproxen, or probenecid is excreted in urine. This study contrasts with previous reports of up to 50% of a dose of ketoprofen and 15--17% of doses of naproxen and probenecid being excreted in urine as the parent compound. Those reports probably reflect primarily the duration of frozen sample storage between collection and assay along with the urine collection schedules employed the speed of the clinical procedures, and the analytical procedures used. Attention should be given to potential conjugate hydrolysis whenever the pharmacokinetics of carboxylic acids are studied.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7452451     DOI: 10.1002/jps.2600691105

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  37 in total

1.  Glucuronidation kinetics of R,S-ketoprofen in adjuvant-induced arthritic rats.

Authors:  C J Meunier; R K Verbeeck
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

2.  Percutaneous absorption of ketoprofen from different anatomical sites in man.

Authors:  A K Shah; G Wei; R C Lanman; V O Bhargava; S J Weir
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

Review 3.  Chirality and nonsteroidal anti-inflammatory drugs.

Authors:  P J Hayball
Journal:  Drugs       Date:  1996       Impact factor: 9.546

4.  S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.

Authors:  Kushari Bowalgaha; David J Elliot; Peter I Mackenzie; Kathleen M Knights; Stellan Swedmark; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

5.  Pharmacokinetic interaction between indomethacin and diflunisal.

Authors:  A Van Hecken; R Verbesselt; T B Tjandra-Maga; P J De Schepper
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Hypoalbuminaemia and naproxen pharmacokinetics in a patient with rheumatoid arthritis.

Authors:  F A Van den Ouweland; F W Gribnau; Y Tan; C A Van Ginneken; L B Van de Putte
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 7.  Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

8.  The disposition of ketoprofen enantiomers in man.

Authors:  B C Sallustio; Y J Purdie; A G Whitehead; M J Ahern; P J Meffin
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

9.  Stereospecific high-performance liquid chromatographic (HPLC) assay of fenoprofen enantiomers in plasma and urine.

Authors:  R Mehvar; F Jamali
Journal:  Pharm Res       Date:  1988-01       Impact factor: 4.200

Review 10.  Non-steroidal anti-inflammatory analgesics other than salicylates.

Authors:  R N Brogden
Journal:  Drugs       Date:  1986       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.